Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Kim
Peter J Neumann

Showing results (141-150 of 436) with videos related to

Pageof 44
Sort By:
The Milbank Quarterly|August 30, 2023
Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated ApprovalPeter J Neumann, Elliott Crummer, James D Chambers, et al.
Health Affairs (Project Hope)|December 8, 2011
Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implementPeter J Neumann, James D Chambers, Françoise Simon, et al.
Annals of Internal Medicine|August 8, 2018
Risk-Targeted Lung Cancer ScreeningVaibhav Kumar, Joshua T Cohen, Peter J Neumann, et al.
Pharmacoeconomics|September 25, 2007
Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the USJoseph A Ladapo, Peter J Neumann, Ron Keren, et al.
Pharmacoeconomics|June 20, 2019
Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics AuthorsJoanna Emerson, Rachel Bacon, Alma Kent, et al.
Health Affairs (Project Hope)|January 6, 2010
Cancer therapy costs influence treatment: a national survey of oncologistsPeter J Neumann, Jennifer A Palmer, Eric Nadler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]Richard J Willke, Peter J Neumann, Louis P Garrison, et al.
Pharmacoeconomics - Open|July 23, 2022
Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness EstimatesRachel Milstein Breslau, Joshua T Cohen, Daniel A Ollendorf, et al.
American Journal of Preventive Medicine|October 17, 2015
Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic ReviewAaron N Winn, Donatus U Ekwueme, Gery P Guy, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Willingness to pay for diagnostic technologies: a review of the contingent valuation literaturePei-Jung Lin, Michael J Cangelosi, David W Lee, et al.
Pageof 44

Showing results (141-150 of 436) with videos related to

Sort By:
Pageof 44
The Milbank Quarterly|August 30, 2023
Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated ApprovalPeter J Neumann, Elliott Crummer, James D Chambers, et al.
Health Affairs (Project Hope)|December 8, 2011
Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implementPeter J Neumann, James D Chambers, Françoise Simon, et al.
Annals of Internal Medicine|August 8, 2018
Risk-Targeted Lung Cancer ScreeningVaibhav Kumar, Joshua T Cohen, Peter J Neumann, et al.
Pharmacoeconomics|September 25, 2007
Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the USJoseph A Ladapo, Peter J Neumann, Ron Keren, et al.
Pharmacoeconomics|June 20, 2019
Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics AuthorsJoanna Emerson, Rachel Bacon, Alma Kent, et al.
Health Affairs (Project Hope)|January 6, 2010
Cancer therapy costs influence treatment: a national survey of oncologistsPeter J Neumann, Jennifer A Palmer, Eric Nadler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]Richard J Willke, Peter J Neumann, Louis P Garrison, et al.
Pharmacoeconomics - Open|July 23, 2022
Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness EstimatesRachel Milstein Breslau, Joshua T Cohen, Daniel A Ollendorf, et al.
American Journal of Preventive Medicine|October 17, 2015
Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic ReviewAaron N Winn, Donatus U Ekwueme, Gery P Guy, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Willingness to pay for diagnostic technologies: a review of the contingent valuation literaturePei-Jung Lin, Michael J Cangelosi, David W Lee, et al.
Pageof 44